Results 221 to 230 of about 1,082,361 (305)

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

Addiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria, Siyan Meng, Alisa A. Padon, Kayla K. Tillett, Scott I. Donaldson, Jon‐Patrick Allem, Matthew E. Rossheim, Cassidy LoParco, Carla J. Berg, Kristina M. Jackson, Julia Chen‐Sankey   +10 more
wiley   +1 more source

Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder. [PDF]

Microbiology (Reading)
Bui TA, O'Croinin BR, Dennett L, Winship IR, Greenshaw AJ.   +4 more
europepmc   +1 more source

Cannabis use and cannabis use disorder among older adults in the USA

Addiction, EarlyView.
Abstract Background and aims Cannabis use is increasing among older adults in the United States (US); however, little is known regarding details of use or cannabis use disorder (CUD) in this population. This study aimed to describe cannabis use and CUD among older adults in the US.
Benjamin H. Han, Evan L. Eschliman, Joseph J. Palamar, Mireia Triguero Roura, Pia M. Mauro   +4 more
wiley   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Addiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke, Johan Duflou, Agata Chrzanowska, Michael Farrell, Julia Lappin, Amy Peacock   +5 more
wiley   +1 more source

Using failure mode and effects analysis for risk management of anesthetic and class I psychotropic drugs in inpatient pharmacy: a pilot study. [PDF]

Sci Rep
Zhang L, He X, Wang Y, Huang L, Du X, Liu M.   +5 more
europepmc   +1 more source

When psychedelic discourse meets local narrative: Selective uptake of psychedelic meanings surrounding mad honey in Nepal

Addiction, EarlyView.
Abstract Aims ‘Mad honey’ is produced when bees collect nectar from Rhododendron species containing grayanotoxins, naturally occurring diterpenoid toxins that can produce dose‐dependent intoxication. It has long been embedded in Nepalese medicinal and ritual practices but has recently become part of global psychedelic discourse. This study examined how
Sharon R. Sznitman, Surendra Tiwari
wiley   +1 more source

Psychotropic Drugs in Dermatology. Part 2: Antipsychotics, Sedative-Hypnotics and Anxiolytics in Dermatology. [PDF]

Indian J Dermatol
Choudhary A, Bose S, Varsha KL, Madke B.
europepmc   +1 more source

Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan, Nazli Tunali, R. Andrew Chambers   +2 more
wiley   +1 more source

Insufficient correctness of package inserts for psychotropic drugs in Germany. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Arning A, Seifert R.
europepmc   +1 more source

Proof‐of‐concept trial of PP‐01 for mitigating cannabis withdrawal syndrome in participants with cannabis use disorder

The American Journal on Addictions, EarlyView.
Abstract Background and Objectives Cannabis withdrawal symptoms can be severe and protracted, significantly impeding the ability to abstain from cannabis use, resulting in failed quit attempts and relapse. This clinical trial evaluated safety and efficacy of PP‐01, a novel dual‑mechanism of action, investigational agent, for mitigating cannabis ...
Ashley F. Slagle, Jay Constantine, Harvey Kushner, Shelli Graham, Ginger Constantine   +4 more
wiley   +1 more source